Synthesis of novel 2-acetamide-5-phenylthio-1,3,4-thiadiazole-containing phenyl urea derivatives as potential VEGFR-2 inhibitors

Arch Pharm (Weinheim). 2022 Mar;355(3):e2100397. doi: 10.1002/ardp.202100397. Epub 2022 Jan 10.

Abstract

A novel series of 2-acetamide-5-phenylthio-1,3,4-thiadiazol derivatives containing a phenyl urea warhead were synthesized and evaluated as antiproliferative agents. The cytotoxic activities of the newly synthesized compounds were evaluated toward three human cancer cell lines, including HT-29, A431, and PC3, as well as normal HDF cells, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. The biological results revealed the highest degree of cytotoxic effects for the 4-chloro-containing compound 9e against the A431 cell line. Further assessment by Western blot analysis assay confirmed the induction of apoptosis by compound 9e, with upregulation of Bax and downregulation of Bcl-2 proteins in A431 cancer cells. In addition, compound 9e inhibited the phosphorylation of vascular endothelial growth factor and its receptor (VEGFR-2) in A431 cancer cells while the total level of actin protein was unchanged. These results were confirmed by a three-dimensional cell culture method using the hanging drop technique.

Keywords: 1,3,4-thiadiazole; 3D cell culture method; VEGFR-2 inhibitory activity; hanging drop technique.

MeSH terms

  • Acetamides / pharmacology
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • Humans
  • Molecular Structure
  • Protein Kinase Inhibitors / pharmacology
  • Structure-Activity Relationship
  • Thiadiazoles
  • Urea / pharmacology
  • Vascular Endothelial Growth Factor A / pharmacology
  • Vascular Endothelial Growth Factor Receptor-2*

Substances

  • Acetamides
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Thiadiazoles
  • Vascular Endothelial Growth Factor A
  • 1,3,4-thiadiazole
  • Urea
  • Vascular Endothelial Growth Factor Receptor-2